Genfit SA (GNFT) has released an update.
GENFIT, a biopharmaceutical company, announced the European Medicines Agency’s positive opinion on Ipsen’s Iqirvo® (elafibranor) for treating Primary Biliary Cholangitis, bringing it closer to EU market authorization. Elafibranor, developed by GENFIT, has been marketed in the US since June 2024 and awaits a final decision in the EU for the second half of 2024. The company continues to focus on advancing treatments for rare liver diseases and has a diverse R&D portfolio.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
